Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay Ltd. has demonstrated significant growth potential, as evidenced by a 43% year-over-year increase in remaining performance obligations, now totaling approximately $70 million. Additionally, the company experienced a 27% rise in the shipment of Deep TMS systems during the fourth quarter of 2025, further supporting its revenue forecast, which has been modestly adjusted upward for 2026 to $66.8 million and projected for 2027 at $81.2 million. The favorable market response following the ProlivRx approval and strategic investments, coupled with the positive trajectory in operating performance, contribute to a robust outlook for the company's financial health and growth.

Bears say

The analysis of BrainsWay Ltd. indicates significant concerns regarding its financial outlook, primarily due to several identified risks. Key factors contributing to this negative perspective include the slower-than-expected adoption of Deep TMS systems, challenges in expanding reimbursement and market access, and difficulties in advancing into additional treatment indications. Additionally, there is a looming risk of long-term dilution, which could further undermine shareholder value.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.